These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36779320)

  • 21. Study on breast carcinoma Her2/neu and hormonal receptors status assessed by automated images analysis systems: ACIS III (Dako) and ScanScope (Aperio).
    Słodkowska J; Filas V; Buszkiewicz E; Trzeciak P; Wojciechowski M; Koktysz R; Staniszewski W; Breborowicz J; Rojo MG
    Folia Histochem Cytobiol; 2010 Jan; 48(1):19-25. PubMed ID: 20529811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study.
    Francis IM; Alath P; George SS; Jaragh M; Al Jassar A; Kapila K
    Diagn Cytopathol; 2016 Dec; 44(12):980-986. PubMed ID: 27666130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunochemistry for oestrogen receptor, progesterone receptor and HER2 on cell blocks in primary breast carcinoma.
    Kumar SK; Gupta N; Rajwanshi A; Joshi K; Singh G
    Cytopathology; 2012 Jun; 23(3):181-6. PubMed ID: 21375607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Estrogen receptors, Progesterone receptors and HER2-neu immunohistochemistry results in breast cancer with those of Oncotype Dx.
    Sughayer MA; Alhassoon S; Sughayer HM
    Ann Diagn Pathol; 2020 Aug; 47():151556. PubMed ID: 32592992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
    Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
    Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pattern of hormone receptors and human epidermal growth factor receptor 2 status in sub-Saharan breast cancer cases: Private practice experience.
    Nwafor CC; Keshinro SO
    Niger J Clin Pract; 2015; 18(4):553-8. PubMed ID: 25966732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Folate Receptor Alpha Immunohistochemistry in Cytology Specimens of Metastatic Breast Carcinoma.
    Sheikh UN; Cohen C; Siddiqui MT
    Acta Cytol; 2015; 59(4):298-304. PubMed ID: 26413911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.
    Liedtke C; Broglio K; Moulder S; Hsu L; Kau SW; Symmans WF; Albarracin C; Meric-Bernstam F; Woodward W; Theriault RL; Kiesel L; Hortobagyi GN; Pusztai L; Gonzalez-Angulo AM
    Ann Oncol; 2009 Dec; 20(12):1953-8. PubMed ID: 19596702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analytic Response Curves of Clinical Breast Cancer IHC Tests.
    Vani K; Sompuram SR; Schaedle AK; Balasubramanian A; Bogen SA
    J Histochem Cytochem; 2017 May; 65(5):273-283. PubMed ID: 28438091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of estrogen, progesterone and HER2 receptors' status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from a tertiary Cancer Center in Saudi Arabia.
    Al-Saleh K; Salah T; Arafah M; Husain S; Al-Rikabi A; Abd El-Aziz N
    PLoS One; 2021; 16(3):e0247802. PubMed ID: 33667252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concordance of breast cancer biomarker testing in core needle biopsy and surgical specimens: A single institution experience.
    Slostad JA; Yun NK; Schad AE; Warrior S; Fogg LF; Rao R
    Cancer Med; 2022 Dec; 11(24):4954-4965. PubMed ID: 35733293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
    Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M;
    BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant.
    Robertson S; Rönnlund C; de Boniface J; Hartman J
    Breast Cancer Res Treat; 2019 Apr; 174(3):795-805. PubMed ID: 30659433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of hormonal receptor immunoexpression and Her2 status in invasive breast cancer after conservative and radical surgery.
    Ţenea-Cojan TŞ; Macovei A; Păun I; Costin AI; Georgescu CV; Georgescu CC; Vladu IM; Ene CG; Radu L
    Rom J Morphol Embryol; 2018; 59(3):763-772. PubMed ID: 30534815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reliability of Her2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma.
    Shabaik A; Lin G; Peterson M; Hasteh F; Tipps A; Datnow B; Weidner N
    Diagn Cytopathol; 2011 May; 39(5):328-32. PubMed ID: 21488175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT.
    Yoon HJ; Kang KW; Chun IK; Cho N; Im SA; Jeong S; Lee S; Jung KC; Lee YS; Jeong JM; Lee DS; Chung JK; Moon WK
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1534-43. PubMed ID: 24652232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Detection in Invasive Breast Carcinoma: A Retrospective Study of 12,467 Patients From 19 Chinese Representative Clinical Centers.
    Shui R; Liang X; Li X; Liu Y; Li H; Xu E; Zhang Z; Lian Y; Guo S; Yao M; Yang H; Xu F; Liu Y; Liu J; Guo D; Wang K; Li J; Ma Y; Wang J; Shi J; Bu H; Yang W
    Clin Breast Cancer; 2020 Feb; 20(1):e65-e74. PubMed ID: 31669267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
    Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
    BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy.
    Krystel-Whittemore M; Xu J; Brogi E; Ventura K; Patil S; Ross DS; Dang C; Robson M; Norton L; Morrow M; Wen HY
    Breast Cancer Res Treat; 2019 Aug; 177(1):61-66. PubMed ID: 31144151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features.
    Ning SF; Li JL; Luo CP; Wei CH; Lu YK; Liu HZ; Wei WE; Zhang LT
    Int J Clin Exp Pathol; 2014; 7(12):8740-7. PubMed ID: 25674240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.